RRRene Romero

Rene Romero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rene Romero has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 502 - Natural History and Risk Factors for Variceal Hemorrhage in Biliary Atresia: Results of a Prospective Multi-Center Longitudinal Analysis

    by Lee Bass, Wen Ye, Kieran Hawthorne, Daniel H. Leung, Karen F. Murray, Jean P. Molleston, Rene Romero, Ronald J. Sokol, Saul J. Karpen, Philip Rosenthal, et al.


  • Open Access

    Extrahepatic Anomalies in Infants With Biliary Atresia: Results of a Large Prospective North American Multicenter Study

    by Kathleen B. Schwarz, Barbara H. Haber, Philip Rosenthal, Cara L. Mack, Jeffrey Moore, Kevin Bove, Jorge A. Bezerra, Saul J. Karpen, Nanda Kerkar, Benjamin L. Shneider, et al.

    The etiology of biliary atresia (BA) is unknown. Given that patterns of anomalies might provide etiopathogenetic clues, we used data from the North American Childhood Liver Disease Research and Education Network to analyze patterns of anomalies in infants with BA. In all, 289 infants who were enrolled in the prospective database prior to surgery at any of 15 participating centers were evaluated. Group 1 was nonsyndromic, isolated BA (without major malformations) (n = 242, 84%), Group 2 was BA and at least one malformation considered major as defined by the National Birth Defects Prevention Study but without laterality defects (n = 17, 6%). Group 3 was syndromic, with laterality defects (n = 30, 10%). In the population as a whole, anomalies (either major or minor) were most prevalent in the cardiovascular (16%) and gastrointestinal (14%) systems. Group 3 patients accounted for the majority of subjects with cardiac, gastrointestinal, and splenic anomalies. Group 2 subjects also frequently displayed cardiovascular (71%) and gastrointestinal (24%) anomalies; interestingly, this group had genitourinary anomalies more frequently (47%) compared to Group 3 subjects (10%). Conclusion: This study identified a group of BA (Group 2) that differed from the classical syndromic and nonsyndromic groups and that was defined by multiple malformations without laterality defects. Careful phenotyping of the patterns of anomalies may be critical to the interpretation of both genetic and environmental risk factors associated with BA, allowing new insight into pathogenesis and/or outcome. (Hepatology 2013;58:1724–1731)


  • Portal Hypertension in Children and Young Adults With Biliary Atresia

    by Benjamin L. Shneider, Bob Abel, Barbara Haber, Saul J. Karpen, John C. Magee, Rene Romero, Kathleen Schwarz, Lee M. Bass, Nanda Kerkar, Alexander G. Miethke, et al.

    Objective: Biliary atresia (BA) frequently results in portal hypertension (PHT), complications of which lead to significant morbidity and mortality. The Childhood Liver Disease Research and Education Network was used to perform a cross‐sectional multicentered analysis of PHT in children with BA.Methods: Subjects with BA receiving medical management at a Childhood Liver Disease Research and Education Network site were enrolled. A priori, clinically evident PHT was defined as “definite” when there was either history of a complication of PHT or clinical findings consistent with PHT (both splenomegaly and thrombocytopenia). PHT was denoted as “possible” if one of the findings was present in the absence of a complication, whereas PHT was “absent” if none of the criteria were met.Results: A total of 163 subjects were enrolled between May 2006 and December 2009. At baseline, definite PHT was present in 49%, possible in 17%, and absent in 34% of subjects. Demographics, growth, and anthropometrics were similar amongst the 3 PHT categories. Alanine aminotransferase, γ‐glutamyl transpeptidase, and sodium levels were similar, whereas there were significant differences in aspartate aminotransferase (AST), AST/alanine aminotransferase, albumin, total bilirubin, prothrombin time, white blood cell count, platelet count, and AST/platelet count between definite and absent PHT. Thirty‐four percent of those with definite PHT had either prothrombin time >15 seconds or albumin <3 g/dL.Conclusions: Clinically definable PHT is present in two‐thirds of North American long‐term BA survivors with their native livers. The presence of PHT is associated with measures of hepatic injury and dysfunction, although in this selected cohort, the degree of hepatic dysfunction is relatively mild and growth is preserved.


  • Open Access

    Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial

    by Robert H. Squires, Anil Dhawan, Estella Alonso, Michael R. Narkewicz, Benjamin L. Shneider, Norberto Rodriguez‐Baez, Dominic Dell Olio, Saul Karpen, John Bucuvalas, Steven Lobritto, et al.

    N-acetylcysteine (NAC) was found to improve transplantation-free survival in only those adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy (HE). Because non-APAP ALF differs significantly between children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in non-APAP PALF. Children from birth through age 17 years with non-APAP ALF enrolled in the PALF registry were eligible to enter an adaptively allocated, doubly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in 5% dextrose in water [D5W]) or placebo (D5W) for up to 7 days. The primary outcome was 1-year survival. Secondary outcomes included liver transplantation-free survival, liver transplantation (LTx), length of intensive care unit (ICU) and hospital stays, organ system failure, and maximum HE score. A total of 184 participants were enrolled in the trial with 92 in each arm. The 1-year survival did not differ significantly ( P = 0.19) between the NAC (73%) and placebo (82%) treatment groups. The 1-year LTx-free survival was significantly lower ( P = 0.03) in those who received NAC (35%) than those who received placebo (53%), particularly, but not significantly so, among those less than 2 years old with HE grade 0-1 (NAC 25%; placebo 60%; P = 0.0493). There were no significant differences between treatment arms for hospital or ICU length of stay, organ systems failing, or highest recorded grade of HE. Conclusion : NAC did not improve 1-year survival in non-APAP PALF. One-year LTx-free survival was significantly lower with NAC, particularly among those


  • 707 MRI Identifies Unsuspected Liver Dysfunction in Patients After Fontan Procedure

    by Pinar Bulut, Rene Romero, Michael McConnell, Kiery Braithwaite, William Mahle, Nitika A. Gupta, Miriam B. Vos, Adina Alazraki

  • A Prospective Clinical Trial Shows That Intravenous N-Acetylcysteine (NAC) Does Not Improve Survival in Pediatric Patients With Non-Acetaminophen Acute Liver Failure

    by Robert Squires, Anil Dhawan, Estella M. Alonso, Michael R. Narkewicz, Norberto Rodriguez-Baez, Deirdre A. Kelly, John Bucuvalas, Saul J. Karpen, Benjamin L. Shneider, Elizabeth B. Rand, et al.


  • Open Access

    Pediatric hepatopulmonary syndrome is seen with polysplenia/interrupted inferior vena cava and without cirrhosis

    by Nitika Arora Gupta, Carlos Abramowsky, Todd Pillen, Douglas Redd, Carlos Fasola, Thomas Heffron, Rene Romero

    Hepatopulmonary syndrome (HPS) is a triad of liver dysfunction, hypoxemia, and intrapulmonary vascular dilatation. We describe the prevalence and clinical features of HPS at a pediatric liver transplant center. Patients referred to Children's Healthcare of Atlanta/Emory University transplant program from February 1999 to May 2005 were reviewed. Oxygen saturation in room air was screened by percutaneous pulse oximetry. HPS cases were compared with similar age non-HPS recipients (n = 38) to determine differences in clinical characteristics, Pediatric End-Stage Liver Disease (PELD) scores, and posttransplantation survival. Of 211 patients referred and 114 patients transplanted, 7 met criteria for HPS (3.3% and 6.1%, respectively). Patients with HPS had lower PELD score (−0.4 ± 5.9 vs. 11 ± 11; P = 0.01) and total bilirubin (1.7 ± 1.1 vs. 11.2 ± 10.1; P = 0.02) at the time of transplantation. Four of 7 patients with HPS had polysplenia/interrupted inferior vena cava (PS/IVC) compared with 0 of 38 age-matched controls (P = 0.0002). Three patients with HPS did not have cirrhosis; 2 of these 3 had PS/IVC. All HPS cases normalized room air oxygen saturation by 6 months, and survival after transplantation in HPS cases was 100%. Marked hepatic synthetic or biochemical dysfunction may not be present, and cirrhosis is not a requirement for the development of HPS in children. HPS in children is frequently associated with PS/IVC. Histologic evidence of abnormal intrahepatic portal vein flow and the demonstration of portosystemic communications at any level should be sought in children presenting with unexplained intrapulmonary vascular dilatation. Liver transplantation for HPS in childhood may be appropriate even in the absence of cirrhosis. Liver Transpl 13:680–686, 2007. © 2007 AASLD.


  • Peripheral eosinophilia and eosinophilic gastroenteritis after pediatric liver transplantation

    by René Romero, Carlos R. Abramowsky, Todd Pillen, Gregory A. Smallwood, Thomas G. Heffron

    Abstract:  Reports indicate peripheral eosinophilia (PE) and gastrointestinal eosinophilic inflammation can occur after pediatric liver transplantation. The incidence of these conditions, potential risk factors, and the impact of PE and gastrointestinal eosinophilic inflammation on liver transplant outcome were determined in this pediatric liver transplant program. Medical records of liver transplant recipients from 1 to 97 and from 12 to 99 were reviewed. Fifty‐seven transplants on 54 patients were performed during the study period. Fifty‐three patients were evaluated; all had normal pre‐transplantation peripheral eosinophil counts. PE of >10% developed in 28% of patients. Using this definition, all such identified patients had absolute eosinophil counts of >350/mm3. History of immediate hypersensitivity did not differ between patients with or without eosinophilia. Gastrointestinal endoscopy and biopsy was performed in 23 patients with gastrointestinal complaints. Of those, six had eosinophilic gastroenteritis and all six had PE. Compared with patients without eosinophilia, those with PE were younger at the time of transplantation (p < 0.05), had more frequent rejection (p < 0.01), were more commonly managed with tacrolimus‐based immunosuppression (p < 0.001), and experienced more frequent episodes of detectable EBV viral load (p < 0.04). Patients with eosinophilic gastroenteritis were more frequently retransplanted (p < 0.006). PE associated with symptomatic eosinophilic gastroenteritis is common after pediatric liver transplantation. Age at transplant, frequency of rejection episodes, tacrolimus‐based immunosuppression, and EBV viral load may be associated with the development of this condition. There may be higher rates of graft loss in such patients. Whether innate immune responsiveness or an acquired immune dysregulation accounts for these findings merits further evaluation.


  • Persistent hyperglycemia in pediatric liver transplant recipients

    by R. Romero, K. Melde, T. Pillen, G.A. Smallwood, T. Heffron


  • 139Peripheral and gastrointestinal eosinophilin after pediatric liver transplantation

    by Rene Romero, Todd Pillen, Rebecca Tutt, Carlos Abramovsky, Gregg Smallwood, Thomas G. Heffron